NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse

• ClinicalTrials.gov Identifier: NCT02348255
• Recruitment Status: Withdrawn
• First Posted: January 28, 2015
• Last Update Posted: January 9, 2018
• Sponsor: University of California, Davis
• Collaborators: National Cancer Institute (NCI); NovoCure Ltd.
• Information provided by (Responsible Party): University of California, Davis

Study Description

Brief Summary:

This phase II trial studies the safety of NovoTTF-100A in combination with bevacizumab and carmustine and to see how well they work in treating patients with glioblastoma multiforme that has returned for the first time. NovoTTF-100A, a type of electric field therapy, delivers low intensity, alternating "wave-like" electric fields that may interfere with multiplication of the glioblastoma multiforme cells. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carmustine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving NovoTTF-100A together with bevacizumab and carmustine may be an effective treatment for glioblastoma multiforme.

Condition or disease	Intervention/treatment	Phase
Adult Brain Glioblastoma; Recurrent Adult Brain Neoplasm	Procedure: Electric Field Therapy; Biological: Bevacizumab; Drug: Carmustine; Other: Quality-of-Life Assessment	Phase 2

Detailed Description:

PRIMARY OBJECTIVES:

I. Establish the safety of NovoTTF-100A in combination with bevacizumab and BCNU (carmustine) in glioblastoma multiforme (GBM) patients who have relapsed after chemoradiation therapy (first relapse).

II. Determine the 6 month overall survival (OS). III. Determine the 6 month progression free survival (PFS). IV. Evaluate the effect of this therapy regimen on quality-of-life.

OUTLINE:

Patients receive bevacizumab intravenously (IV) over 30-90 minutes every 2 weeks beginning on day -7 for up to 13 doses and carmustine IV over 4 hours every 8 weeks beginning on day 1 for up to 3 doses. Patients also undergo NovoTTF-100A according to standard procedures starting one week before the first dose of carmustine.

After completion of study treatment, patients are followed up for 12 months.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 0 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase II, Multi-institutional Trial of NOVO-TTF-100A, BCNU and Bevacizumab for GBM in First Relapse
• Actual Study Start Date: January 2016
• Actual Primary Completion Date: January 2017
• Actual Study Completion Date: January 2017

Arms and Interventions

Arm	Intervention/treatment
Experimental: Treatment (bevacizumab, carmustine, NovoTTF-100A); Patients receive bevacizumab IV over 30-90 minutes every 2 weeks beginning on day -7 for up to 13 doses and carmustine IV over 4 hours every 8 weeks beginning on day 1 for up to 3 doses. Patients also undergo NovoTTF-100A according to standard procedures starting one week before the first dose of carmustine.	Procedure: Electric Field Therapy; Undergo NovoTTF-100A; Biological: Bevacizumab; Given IV; Other Names: Avastin; rhuMab-VEGF; Drug: Carmustine; Given IV; Other Name: FDA 0345; Other: Quality-of-Life Assessment; Ancillary studies; Other Name: Quality of Life Assessment

Outcome Measures

Primary Outcome Measures :

1. Incidence of adverse events, assessed by National Cancer Institute-Common Terminology Criteria 4.0 toxicity criteria [ Time Frame: Up to 12 months ]
   Toxicity summaries will be provided for all subjects who have received any part of the study treatment. Statistical analysis will include estimates of proportions with each class of toxicity with a 95% confidence interval.
2. Progression Free Survival [ Time Frame: Time from first day of treatment to the first observation of disease progression or death due to any cause, assessed up to 6 months ]
   Will be estimated using the product-limit method of Kaplan and Meier.
3. Overall Survival [ Time Frame: Time from first day of treatment to time of death due to any cause, assessed up to 6 months ]
   Will be estimated using the product-limit method of Kaplan and Meier.
4. Quality of life as measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and BN-20 brain cancer module [ Time Frame: Up to 6 months ]
5. Change in tumor volume using magnetic resonance imaging (MRI) [ Time Frame: Baseline to day 168 ]
   Mean change in linear dimension will be evaluated for shrinkage using a paired t-test. If the assumption of normality is violated, a signed rank test will be used. The Response Assessment in Neuro-oncology (RANO) criteria will be part of the MRI evaluation.
6. Change in linear dimension using MRI [ Time Frame: Baseline to day 168 ]
   Mean change in linear dimension will be evaluated for shrinkage using a paired t-test. If the assumption of normality is violated, a signed rank test will be used. The RANO criteria will be part of the MRI evaluation.

Eligibility Criteria

• Ages Eligible for Study: 22 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Histologically confirmed GBM
• Progressive disease after temozolomide and radiation therapy (in "first relapse")
• At least 28 days since chemotherapy or radiation
• Karnofsky performance score at least 70%
• Platelet count >= 130/mm^3
• Absolute neutrophil count >= 1500/mm^3
• Calculated creatinine clearance greater than 45 mg/dl using the Cockcroft-Gault formula
• Aspartate aminotransferase (AST) < 2 times the upper limit of normal
• Bilirubin < 1.5 times the upper limit of normal
• Subjects with child-bearing potential agree to use effective means of contraception

Exclusion Criteria:

• Prior systemically administered nitrosoureas or vascular endothelial growth factor (VEGF) targeted therapy
• Chemotherapy for glioma other than temozolomide or Gliadel wafers (steroids are allowed)
• Pregnant or breast feeding
• Active inflammatory bowel disease
• Abdominal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess within 6 months
• Hypertension: systolic blood pressure (SBP) > 150 or diastolic blood pressure (DBP) > 100 mm mercury (Hg) despite antihypertensive medications
• New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF); myocardial infarction or unstable angina within 6 months
• History of thrombosis
• Symptomatic peripheral vascular disease, stroke or transient ischemic attack within 6 months
• Bleeding risks: Required to be on therapeutic anticoagulation (aspirin is allowed), coagulopathy (e.g. hemophilia or von Willebrand's disease); any grade III or greater hemorrhage, major surgical procedure, or significant trauma within 28 days; core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days
• Activated partial thromboplastin time (APTT) must not exceed 32.5 seconds (normal range 21.8-31.5 seconds); international normalized ratio (INR) must not exceed 1.30 (normal range 0.87-1.18)
• Serious, non-healing wound, ulcer, or bone fracture
• Active implanted medical device (e.g. deep brain stimulators, spinal cord stimulators, vagus nerve stimulators, pacemakers, defibrillators, and programmable shunts), a skull defect (such as missing bone with no replacement), a shunt, or bullet fragments
• Known sensitivity to conductive hydrogels like the gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes
• Human immunodeficiency virus (HIV) positive
• Proteinuria at screening as demonstrated by urine dipstick >= 2+
• Prior organ transplantation
• Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
• Aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), clopidogrel or any other drug whose goal is to inhibit platelet function
• Unable to give signed informed consent

Contacts and Locations

Locations

United States, California

University of California Davis Comprehensive Cancer Center

Sacramento, California, United States, 95817

United States, Georgia

Piedmont Hospital

Atlanta, Georgia, United States, 30309

Sponsors and Collaborators

University of California, Davis

National Cancer Institute (NCI)

NovoCure Ltd.

Investigators

• Principal Investigator: Robert O'Donnell; University of California, Davis

More Information

• Responsible Party: University of California, Davis
• ClinicalTrials.gov Identifier: NCT02348255
• Other Study ID Numbers: UCDCC#249; 663113 ( Other Identifier: UC Davis ); UCDCC#249 ( Other Identifier: University of California Davis Comprehensive Cancer Center ); P30CA093373 ( U.S. NIH Grant/Contract ); NCI-2014-02628 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
• First Posted: January 28, 2015
• Last Update Posted: January 9, 2018
• Last Verified: January 2018

Additional relevant MeSH terms:

Glioblastoma; Brain Neoplasms; Astrocytoma; Glioma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue; Central Nervous System Neoplasms; Nervous System Neoplasms; Neoplasms by Site; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Bevacizumab; Carmustine; Antineoplastic Agents, Immunological; Antineoplastic Agents; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Physiological Effects of Drugs; Growth Inhibitors; Antineoplastic Agents, Alkylating; Alkylating Agents; Molecular Mechanisms of Pharmacological Action